Acceptability of the R21/Matrix-M malaria vaccine alongside existing malaria interventions in the trial context
The R21/Matrix-M vaccine was acceptable to caregivers and communities of participants in the R21/Matrix-M phase III trial in Mali. Implementation research is needed to evaluate and ensure co-coverage of complementary malaria control interventions, including SMC in seasonal settings, in the face of the scale-up of R21/Matrix-M and other malaria vaccines.
Authors
- Jane Grant (ORCID: https://orcid.org/0000-0002-1607-4042)
- Alassane Dicko (ORCID: https://orcid.org/0000-0003-2153-8427)
- Jayne Webster (ORCID: https://orcid.org/0000-0002-0498-8883)
- Halimatou Diawara (ORCID: https://orcid.org/0000-0001-5361-1532)
- Daniel Chandramohan (ORCID: https://orcid.org/0000-0002-6974-5620)
- Brian Greenwood (ORCID: https://orcid.org/0000-0001-5725-9118)
- Issaka Sagara (ORCID: https://orcid.org/0000-0002-8555-9983)
- Djibrilla Issiaka
- Adrian V. S. Hill (ORCID: https://orcid.org/0000-0003-0900-9629)
- Fatoumata Koita
- Seydou Traoré (ORCID: https://orcid.org/0000-0003-3568-2788)
- Mehreen Datoo
- Mala Sylla
Institutions
- Ministère de la Santé et de l'Hygiène Publique (ML)
- University of Oxford (GB)
- London School of Hygiene & Tropical Medicine (GB)
- Université des Sciences, des Techniques et des Technologies de Bamako (ML)
- Jenner Institute (GB)
Publication Details
- Journal
- BMJ Global Health
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/bmjgh-2024-015524
- Citations
- 3
- Primary Topic
- Malaria Research and Control
- Type
- article
- Field-Weighted Citation Impact
- 5.64
Funders
- University of Oxford